Skip to main content

Advertisement

Table 1 Clinicopathologic parameters, FOXM1 expression and survival analysis

From: Prognostic significance of FOXM1 expression and antitumor effect of FOXM1 inhibition in synovial sarcomas

Variable No. of patients Analyzed groups P-value FOXM1
OS EFS Positive Negative P-value
Sex        
 Male 44     13 31  
 Female 62 Male vs. female 0.0028* 0.3047 17 45 0.811
Age        
  < 20 19     4 15  
  ≥ 20 87 20 < vs. ≥20 0.0189* 0.2499 26 61 0.4279
Chemotherapy        
 Yes 25     6 19  
 No 25 Yes vs. No 0.3431 0.8037 4 21 0.4783
 N.A. 56       
Fusion gene type        
 SS18-SSX1 30     11 19  
 SS18-SSX2 14 SSX1 vs. SSX2 0.6271 0.8581 3 11 0.3736
 N.A. 62       
Depth        
 Superficial 13     5 8  
 Deep 91 Deep vs. Superficial 0.4441 0.9057 25 66 0.4243
 N.A. 2       
Size,cm        
  < 5 40     8 32  
 5≥ 62 <5 vs. 5≤ 0.0012* 0.0335* 22 40 0.0885
 N.A. 4       
Histological subtype        
 Mono 69     22 47  
 Bi 26 Mono vs. bi 0.4225 0.9701 3 23 0.0335*
 Poor 3     1 2  
 Undetermined 8       
Necrosis        
 None 56     13 43  
  ≤ 50 % 26 Necrosis (+) vs. (−) <0.001* 0.0012* 9 17 0.1526
  > 50 % 15     6 9  
 N.A. 9       
Mitotic count        
  ≥ 10/10HPF 70     12 58  
  < 10/10HPF 31 ≥10 vs. <10/10HPF 0.0344* 0.0056* 17 14 0.0002*
 N.A. 5       
AJCC stage        
 II 39 II vs. III 0.0304* 0.3734 11 28 0.72
 III 44 III vs. IV <0.001* - 14 30 0.6579
 IV 13     5 8  
 N.A. 10       
FNCLCC        
 2 69     18 51  
 3 23 2 vs. 3 <0.001* <0.001* 10 13 0.123
 N.A. 14       
FOXM1        
 Positive 30       
 Negative 76 Positive vs. negative 0.0128* 0.0043* - - -
  1. AJCC American Joint Committee on Cancer, Bi biphasic synovial sarcoma, EFS event-free survival, FNCLCC French Federation of Cancer Centers, HPF high-power fields, Mono monophasic synovial sarcoma, Poor poorly differentiated synovial sarcoma, NA not available, OS overall survival
  2. *P < 0.05 by log-rank test or chi-square test